Literature DB >> 24361114

Secondary stroke prevention.

Graeme J Hankey1.   

Abstract

Survivors of stroke and transient ischaemic attacks are at risk of a recurrent stroke, which is often more severe and disabling than the index event. Optimum secondary prevention of recurrent stroke needs rapid diagnosis and treatment and prompt identification of the underlying cardiovascular cause. Effective treatments include organised acute assessment and intervention with antithrombotic therapy, carotid revascularisation, and control of causal risk factors, as appropriate. However, effective treatments are not implemented optimally in clinical practice. Recurrent strokes continue to account for 25-30% of all strokes and represent unsuccessful secondary prevention. Immediate and sustained implementation of effective and appropriate secondary prevention strategies in patients with first-ever stroke or transient ischaemic attack has the potential to reduce the burden of stroke by up to a quarter.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24361114     DOI: 10.1016/S1474-4422(13)70255-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  81 in total

1.  Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.

Authors:  Lanting Yang; Maria M Brooks; Nancy W Glynn; Yuting Zhang; Samir Saba; Inmaculada Hernandez
Journal:  Am J Cardiol       Date:  2020-04-10       Impact factor: 2.778

Review 2.  Predictive and individualized management of stroke-success story in Czech Republic.

Authors:  Jiri Polivka; Jiri Polivka; Vladimir Rohan
Journal:  EPMA J       Date:  2018-10-25       Impact factor: 6.543

Review 3.  [Ability to drive with cerebrovascular diseases : Position paper of the German societies DGNB, DGN, DGNC, DGNR, DSG and GNP].

Authors:  P Marx; G F Hamann; O Busse; T Mokrusch; H Niemann; H Vatter; B Widder
Journal:  Nervenarzt       Date:  2019-04       Impact factor: 1.214

4.  Kolaviron, a Garcinia kola biflavonoid complex, protects against ischemia/reperfusion injury: pertinent mechanistic insights from biochemical and physical evaluations in rat brain.

Authors:  Afolabi C Akinmoladun; Bolanle L Akinrinola; M Tolulope Olaleye; Ebenezer O Farombi
Journal:  Neurochem Res       Date:  2015-02-01       Impact factor: 3.996

5.  Physical fitness interventions for nonambulatory stroke survivors: A mixed-methods systematic review and meta-analysis.

Authors:  Megan Lloyd; Dawn A Skelton; Gillian E Mead; Brian Williams; Frederike van Wijck
Journal:  Brain Behav       Date:  2018-06-19       Impact factor: 2.708

6.  Chromosome 4q25 Variants and Age at Onset of Ischemic Stroke.

Authors:  Lingli Sun; Ling Tian; Jian Xu; Zhizhong Zhang; Xinfeng Liu
Journal:  Mol Neurobiol       Date:  2016-05-12       Impact factor: 5.590

7.  Recurrent stroke in midlife is associated with not having a primary care physician.

Authors:  Rebecca J Lank; Lynda D Lisabeth; Brisa N Sánchez; Darin B Zahuranec; Kevin A Kerber; Lesli E Skolarus; James F Burke; Deborah A Levine; Erin Case; Devin L Brown; Lewis B Morgenstern
Journal:  Neurology       Date:  2019-01-04       Impact factor: 9.910

8.  [New aspects of stroke medicine].

Authors:  H C Diener; B Frank; K Hajjar; C Weimar
Journal:  Nervenarzt       Date:  2014-08       Impact factor: 1.214

Review 9.  Post-stroke medication adherence and persistence rates: a meta-analysis of observational studies.

Authors:  Jia Zhang; Yanhong Gong; Yuxin Zhao; Nan Jiang; Jing Wang; Xiaoxv Yin
Journal:  J Neurol       Date:  2019-12-02       Impact factor: 4.849

10.  Secondary stroke prevention services in Canada: a cross-sectional survey and geospatial analysis of resources, capacity and geographic access.

Authors:  Lauren Jewett; Adil Harroud; Michael D Hill; Robert Côté; Theodore Wein; Eric E Smith; Gord Gubitz; Andrew M Demchuk; Demetrios J Sahlas; David J Gladstone; M Patrice Lindsay
Journal:  CMAJ Open       Date:  2018-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.